October 26, 2021
Life Sciences
  • Moderna released trial results for its COVID-19 vaccine for children aged 6 to 11, saying it provides a “robust” immune response after two doses. The company said that two 50-microgram doses of the vaccine, half the dosage given to adults, produced antibody levels that were 1.5 times higher than those seen in young adults. Moderna plans to officially submit the results to the FDA for authorization in “the near term.” (Articles here, here, here, here, and here)
  • Eli Lilly & Co. said that its COVID-19 antibody treatments brought in $217 million in the third quarter, up from $149 million in the second quarter. Increased hospitalizations tied to the delta variant fueled greater demand for the therapies, which the drugmaker expects will continue for the rest of the year. Eli Lilly also said it launched a rolling submission for its experimental Alzheimer’s disease treatment. (Article here)